Protagonist Therapeutics, Inc. (PTGX) financial statements (2021 and earlier)

Company profile

Business Address 7707 GATEWAY BLVD., SUITE 140
NEWARK, CA 94560-1160
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments306194209118133138126
Cash and cash equivalents1178414660335071
Short-term investments18811062571008755
Restricted cash and investments0000000
Receivables4334726
Prepaid expense2   2  
Other undisclosed current assets4765345
Total current assets:316204217126145144137
Noncurrent Assets
Operating lease, right-of-use asset5566667
Property, plant and equipment1122222
Long-term investments and receivables26     
Long-term investments26     
Restricted cash and investments0000000
Deferred income tax assets   1122
Total noncurrent assets:91389101111
TOTAL ASSETS:324217225135155155148
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities22181615151214
Accounts payable3334323
Accrued liabilities18161312121011
Deferred revenue14171719181618
Debt   1111
Due to related parties3211111
Other undisclosed current liabilities111    
Total current liabilities:40393536353133
Noncurrent Liabilities
Long-term debt and lease obligation5556667
Operating lease, liability5556667
Liabilities, other than long-term debt041720242224
Deferred revenue 41720242224
Other liabilities000    
Other undisclosed noncurrent liabilities   1010  
Total noncurrent liabilities:592236402830
Total liabilities:45485772755964
Stockholders' equity
Stockholders' equity attributable to parent28017016763809584
Additional paid in capital563435425300298296268
Accumulated other comprehensive income (loss)0(0)(0)0(0)(0)(0)
Accumulated deficit(284)(265)(257)(238)(218)(200)(184)
Total stockholders' equity:28017016763809584
TOTAL LIABILITIES AND EQUITY:324217225135155155148

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Sublease income    000
Gross profit:    000
Operating expenses(24)(21)(24)(23)(20)(21)(23)
Other undisclosed operating income (loss)6136434(8)
Operating loss:(19)(8)(18)(20)(17)(17)(31)
Nonoperating income0010111
Investment income, nonoperating0001 11
Other nonoperating income (expense)(0)(0)1(0)   
Interest and debt expense(0)(0)(1)(0)   
Other undisclosed loss from continuing operations before equity method investments, income taxes    (0)  
Loss from continuing operations before income taxes:(19)(8)(18)(20)(17)(17)(31)
Income tax expense (benefit)  (1)(0)(1)02
Net loss available to common stockholders, diluted:(19)(8)(19)(20)(18)(16)(29)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(19)(8)(19)(20)(18)(16)(29)
Comprehensive loss:(19)(8)(19)(20)(18)(16)(29)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)0(0)00
Comprehensive loss, net of tax, attributable to parent:(19)(8)(20)(20)(18)(16)(29)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: